Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study
Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CA...
Saved in:
Published in | The journal of clinical endocrinology and metabolism Vol. 101; no. 8; pp. 3134 - 3143 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Oxford University Press
01.08.2016
Copyright by The Endocrine Society |
Subjects | |
Online Access | Get full text |
ISSN | 0021-972X 1945-7197 1945-7197 |
DOI | 10.1210/jc.2016-1525 |
Cover
Loading…
Abstract | Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CAC score.Design and Setting:This study is a longitudinal cohort study performed in a healthcare center.Participants:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.Main Outcome Measures:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.Results:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).Conclusions:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.We investigated the association between NAFLD and CAC. NAFLD significantly affected the development of CAC, but not the progression. The severity of NAFLD was also associated with CAC development. |
---|---|
AbstractList | Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.
This study investigated the longitudinal association between NAFLD and CAC score.
This study is a longitudinal cohort study performed in a healthcare center.
Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.
CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.
More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01-2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).
NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors. Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.CONTEXTNonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.This study investigated the longitudinal association between NAFLD and CAC score.OBJECTIVEThis study investigated the longitudinal association between NAFLD and CAC score.This study is a longitudinal cohort study performed in a healthcare center.DESIGN AND SETTINGThis study is a longitudinal cohort study performed in a healthcare center.Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.PARTICIPANTSAmong 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.MAIN OUTCOME MEASURESCAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01-2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).RESULTSMore subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01-2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.CONCLUSIONSNAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors. Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CAC score.Design and Setting:This study is a longitudinal cohort study performed in a healthcare center.Participants:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.Main Outcome Measures:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.Results:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).Conclusions:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors. Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown.Objective:This study investigated the longitudinal association between NAFLD and CAC score.Design and Setting:This study is a longitudinal cohort study performed in a healthcare center.Participants:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography.Main Outcome Measures:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed.Results:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043).Conclusions:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.We investigated the association between NAFLD and CAC. NAFLD significantly affected the development of CAC, but not the progression. The severity of NAFLD was also associated with CAC development. CONTEXT:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself affects CAC development or progression remains unknown. OBJECTIVE:This study investigated the longitudinal association between NAFLD and CAC score. DESIGN AND SETTING:This study is a longitudinal cohort study performed in a healthcare center. PARTICIPANTS:Among 1732 subjects who underwent serial CAC evaluation, we evaluated 846 subjects with NAFLD and 886 subjects without NAFLD, as diagnosed via ultrasonography. MAIN OUTCOME MEASURES:CAC score was compared at baseline and follow-up. In subjects without calcification (CAC score = 0) at baseline, any incidental calcification (CAC score >0) at follow-up was defined as development of CAC. In subjects with CAC (CAC score > 0) at baseline, confirmed CAC aggravation was defined as progression. Logistic regression analysis was performed. RESULTS:More subjects with NAFLD than without showed CAC development or progression (48.8 vs 38.4%; P < .001). The impact of NAFLD on a change in CAC score significantly differed according to the CAC score at baseline. In subjects without calcification at baseline, NAFLD significantly affected the development of calcification (odds ratio, 1.49; 95% confidence interval, 1.01–2.21; P = .045) after adjusting for traditional metabolic risk factors. However, in subjects with baseline CAC, NAFLD did not significantly affect progression (P = .734). Additionally, the severity of NAFLD was important. The severity of NAFLD was dose-dependently associated with the development of CAC (P for trend = .043). CONCLUSIONS:NAFLD plays a role in the early development of CAC, but not the progression. Ultrasonographic severity of NAFLD is dose-dependently associated with CAC development in subjects with a CAC score of 0 at baseline, independent of traditional risk factors.We investigated the association between NAFLD and CAC. NAFLD significantly affected the development of CAC, but not the progression. The severity of NAFLD was also associated with CAC development. |
Author | Kim, Min-Kyung Cha, Myung-jin Choi, Su-Yeon Park, Hyo Eun Kwak, Min-Sun Kim, Donghee |
AuthorAffiliation | Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea |
AuthorAffiliation_xml | – name: Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea |
Author_xml | – sequence: 1 givenname: Hyo Eun surname: Park fullname: Park, Hyo Eun organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea – sequence: 2 givenname: Min-Sun surname: Kwak fullname: Kwak, Min-Sun organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea – sequence: 3 givenname: Donghee surname: Kim fullname: Kim, Donghee email: messmd@chol.com organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea – sequence: 4 givenname: Min-Kyung surname: Kim fullname: Kim, Min-Kyung organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea – sequence: 5 givenname: Myung-jin surname: Cha fullname: Cha, Myung-jin organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea – sequence: 6 givenname: Su-Yeon surname: Choi fullname: Choi, Su-Yeon email: sychoi9@gmail.com organization: 1Department of Internal Medicine, Healthcare System Gangnam Center, Seoul National University Hospital, 135-984 Seoul, Korea |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27253666$$D View this record in MEDLINE/PubMed |
BookMark | eNp1ksFvFCEUxompsdvqzbMh8VAPTvtgZmCmt83WapONPajRG6HMG5eVHbbAtNn_XqbbXpqUhDwgv-89-B5H5GDwAxLynsEp4wzO1uaUAxMFq3n9isxYW9WFZK08IDMAzopW8j-H5CjGNQCrqrp8Qw655HUphJiR-N0P2hm_8s4aeqlT2tGlvcNAL2xEHZFeRTqP0RurE3b0t00ruvAhq8KOzkPCHBY5g-2t0cn6gV7gHTq_3eCQzumcLv3w16axs7kO_ZEXu7fkda9dxHeP8Zj8uvzyc_GtWF5_vVrMl4UpW8GLUvSg66bWOr9GVG3PoGFoOqgrIUFquNEd5lOOpq8AG9FoU0kwvENTy16Ux-TTPu82-NsRY1IbGw06pwf0Y1SsgVZAKdiEfnyGrv0Y8o2jKpmoSslbCZn68EiNNxvs1DbYTbZBPdmZAb4HTPAxBuyVsenBlRS0dYqBmnqm1kZNPVNTz7Lo8zPRU94X8GqP33uX3Y__3HiPQa1Qu7RSkEe2pykmATR5V-TJeZad7GV-3L5U4OEPlf8BYb2ylQ |
CitedBy_id | crossref_primary_10_12998_wjcc_v8_i20_4688 crossref_primary_10_1016_j_abb_2020_108679 crossref_primary_10_1136_openhrt_2021_001850 crossref_primary_10_1371_journal_pone_0301126 crossref_primary_10_1038_s41598_020_61750_4 crossref_primary_10_5812_hepatmon_122772 crossref_primary_10_1016_j_dld_2018_04_027 crossref_primary_10_1007_s12350_019_01783_z crossref_primary_10_1161_CIRCIMAGING_124_017376 crossref_primary_10_1186_s12872_024_03880_5 crossref_primary_10_1016_j_alcohol_2020_07_010 crossref_primary_10_1371_journal_pone_0224626 crossref_primary_10_1016_j_atherosclerosis_2018_03_027 crossref_primary_10_1007_s11604_021_01113_9 crossref_primary_10_1016_j_atherosclerosis_2016_11_021 crossref_primary_10_3390_life12081189 crossref_primary_10_3390_ijerph16183415 crossref_primary_10_1371_journal_pone_0180118 crossref_primary_10_5009_gnl19069 crossref_primary_10_1007_s12350_019_01736_6 crossref_primary_10_1016_j_cgh_2023_09_018 crossref_primary_10_1016_j_jacc_2018_11_050 crossref_primary_10_1016_j_jhep_2017_09_021 crossref_primary_10_1111_eci_14188 crossref_primary_10_1038_s41598_017_09851_5 crossref_primary_10_1111_apt_17869 crossref_primary_10_1016_S2468_1253_24_00310_8 crossref_primary_10_2174_1381612826666200417142444 crossref_primary_10_3350_cmh_2020_0239 crossref_primary_10_1155_2020_8489238 crossref_primary_10_2478_rjim_2018_0009 crossref_primary_10_1016_j_cpcardiol_2023_102065 crossref_primary_10_15829_1560_4071_2023_5552 crossref_primary_10_1007_s00535_018_1516_5 crossref_primary_10_1186_s12933_022_01725_z crossref_primary_10_1111_echo_13545 crossref_primary_10_1097_CRD_0000000000000537 crossref_primary_10_1186_s13098_025_01577_z crossref_primary_10_1016_j_clnesp_2020_03_003 crossref_primary_10_1016_j_dsx_2023_102938 crossref_primary_10_1038_s41598_025_88133_x crossref_primary_10_14814_phy2_13386 crossref_primary_10_1016_j_cgh_2021_09_021 crossref_primary_10_2147_DMSO_S426102 crossref_primary_10_1136_jech_2018_210943 crossref_primary_10_3390_ijms251910595 crossref_primary_10_34172_mejdd_2020_166 crossref_primary_10_1111_liv_15591 crossref_primary_10_3904_kjim_2017_343 crossref_primary_10_1016_j_dld_2017_12_014 crossref_primary_10_3390_jcm10081569 crossref_primary_10_1371_journal_pone_0202325 |
ContentType | Journal Article |
Copyright | Copyright © 2016 by the Endocrine Society 2016 Copyright © 2016 by The Endocrine Society Copyright © 2016 by the Endocrine Society |
Copyright_xml | – notice: Copyright © 2016 by the Endocrine Society 2016 – notice: Copyright © 2016 by The Endocrine Society – notice: Copyright © 2016 by the Endocrine Society |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QP 7T5 7TM H94 K9. 7X8 |
DOI | 10.1210/jc.2016-1525 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Calcium & Calcified Tissue Abstracts Immunology Abstracts Nucleic Acids Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Calcium & Calcified Tissue Abstracts Nucleic Acids Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1945-7197 |
EndPage | 3143 |
ExternalDocumentID | 27253666 10_1210_jc_2016_1525 00004678-201608000-00022 10.1210/jc.2016-1525 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -~X .55 .XZ 08P 0R~ 18M 1TH 29K 2WC 34G 354 39C 4.4 48X 53G 5GY 5RS 5YH 8F7 AABZA AACZT AAIMJ AAPQZ AAPXW AARHZ AAUAY AAVAP AAWTL ABBLC ABDFA ABEJV ABGNP ABJNI ABLJU ABMNT ABNHQ ABOCM ABPMR ABPPZ ABPQP ABPTD ABQNK ABVGC ABWST ABXVV ACGFO ACGFS ACPRK ACUTJ ACYHN ADBBV ADGKP ADGZP ADHKW ADQBN ADRTK ADVEK AELWJ AEMDU AENEX AENZO AETBJ AEWNT AFCHL AFFZL AFGWE AFOFC AFRAH AFXAL AGINJ AGKRT AGQXC AGUTN AHMBA AHMMS AJEEA ALMA_UNASSIGNED_HOLDINGS APIBT ARIXL ASPBG ATGXG AVWKF AZFZN BAWUL BAYMD BCRHZ BEYMZ BSWAC BTRTY C45 CDBKE CS3 D-I DAKXR DIK E3Z EBS EJD EMOBN ENERS F5P FECEO FHSFR FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 HZ~ H~9 KBUDW KOP KQ8 KSI KSN L7B M5~ MHKGH MJL N9A NLBLG NOMLY NOYVH NVLIB O9- OAUYM OBH OCB ODMLO OFXIZ OGEVE OHH OJZSN OK1 OPAEJ OVD OVIDX P2P P6G REU ROX ROZ TEORI TJX TLC TR2 TWZ VVN W8F WOQ X7M YBU YFH YHG YOC YSK ZY1 ~02 ~H1 .GJ 3O- 7X7 88E 8FI 8FJ AAJQQ AAKAS AAPGJ AAQQT AAUQX AAWDT AAYJJ ABDPE ABUWG ABXZS ACFRR ACVCV ACZBC ADMTO ADNBA ADZCM AEMQT AEOTA AERZD AFFNX AFFQV AFKRA AFYAG AGMDO AGORE AHGBF AI. AJBYB AJDVS ALXQX APJGH AQDSO AQKUS AVNTJ BENPR BPHCQ BVXVI CCPQU EIHJH FEDTE FYUFA HMCUK HVGLF IAO IHR INH ITC J5H M1P MBLQV N4W NU- OBFPC PHGZM PHGZT PQQKQ PROAC PSQYO TMA UKHRP VH1 WHG X52 ZGI ZXP AAYXX CITATION 3V. CGR CUY CVF ECM EIF NPM VXZ 7QP 7T5 7TM H94 K9. 7X8 |
ID | FETCH-LOGICAL-c3962-36f0a585aa197649f1081ecd0546707a0bade9f12ecf40e868ac470c2dec57f63 |
ISSN | 0021-972X 1945-7197 |
IngestDate | Thu Sep 04 18:09:45 EDT 2025 Mon Jun 30 12:45:29 EDT 2025 Wed Feb 19 02:42:38 EST 2025 Tue Jul 01 01:10:41 EDT 2025 Thu Apr 24 23:08:49 EDT 2025 Fri May 16 04:02:33 EDT 2025 Fri Feb 07 10:35:42 EST 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3962-36f0a585aa197649f1081ecd0546707a0bade9f12ecf40e868ac470c2dec57f63 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
PMID | 27253666 |
PQID | 3164372970 |
PQPubID | 2046206 |
PageCount | 10 |
ParticipantIDs | proquest_miscellaneous_1809603616 proquest_journals_3164372970 pubmed_primary_27253666 crossref_citationtrail_10_1210_jc_2016_1525 crossref_primary_10_1210_jc_2016_1525 wolterskluwer_health_00004678-201608000-00022 oup_primary_10_1210_jc_2016-1525 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 20160801 2016-August 2016-08-00 |
PublicationDateYYYYMMDD | 2016-08-01 |
PublicationDate_xml | – month: 08 year: 2016 text: 20160801 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Washington |
PublicationTitle | The journal of clinical endocrinology and metabolism |
PublicationTitleAlternate | J Clin Endocrinol Metab |
PublicationYear | 2016 |
Publisher | Oxford University Press Copyright by The Endocrine Society |
Publisher_xml | – name: Oxford University Press – name: Copyright by The Endocrine Society |
SSID | ssj0014453 |
Score | 2.4231045 |
Snippet | Context:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD... CONTEXT:Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD... Nonalcoholic fatty liver disease (NAFLD) is associated with coronary artery calcification (CAC) in cross-sectional studies. However, whether NAFLD itself... |
SourceID | proquest pubmed crossref wolterskluwer oup |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 3134 |
SubjectTerms | Aged Calcification Calcification (ectopic) Calcinosis - complications Calcinosis - diagnosis Calcinosis - epidemiology Calcinosis - pathology Coronary artery Coronary Artery Disease - complications Coronary Artery Disease - diagnosis Coronary Artery Disease - epidemiology Coronary Artery Disease - pathology Coronary vessels Disease Progression Fatty liver Female Humans Liver - diagnostic imaging Liver diseases Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease - complications Non-alcoholic Fatty Liver Disease - diagnosis Non-alcoholic Fatty Liver Disease - epidemiology Retrospective Studies Risk factors Severity of Illness Index Ultrasonography |
Title | Nonalcoholic Fatty Liver Disease Is Associated With Coronary Artery Calcification Development: A Longitudinal Study |
URI | https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004678-201608000-00022 https://www.ncbi.nlm.nih.gov/pubmed/27253666 https://www.proquest.com/docview/3164372970 https://www.proquest.com/docview/1809603616 |
Volume | 101 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKkBAIIb4pDGQkeKqM8uE4LW_V2LTBtpdtom-R4zga-0gm0mgqfwZ_MXe2k7qDSsBLVDnXOMr9cr5z7n5HyLsJ12XJ84SJOMwZT1LF5LiQbCxFoUQRysRs6B8cit0T_nmWzAaDn17WUjvPP6gff6wr-R-twhjoFatk_0Gz_UVhAH6DfuEIGobjX-n4EN1o0-L2mxrtyDk41PuYZ4GcmvjZZbTX9M8fHMuvuOe6hZQFmCo3xWTOBRZnmbQ8CwQvh8jWrO_X2NCoLUzzrKOei_ZsCTKPe6Ivs9RVUYM5qpYET5d6DnC76AgLXb21WfgW9Wi7XSYDXMtzm89fsSNv2HZ9_gS3c6r1jVGU_bJo3SLs9jBC0WfQwRJk7e6EJywNbapub5idiEXg2DOzcWh3QH-z_xDAov1HbkqYBXs7-WLw4K4uDRaiNEpiIW6QcJtlvTt1i9yOIPQw7UBmfdoQxJ9J7AoosPrJnwqJpd2fV7yclcpJL4C5R-5f15gT0ZybkgjPsTl-SB64iIROLbwekYGuHpM7By7n4glpfJRRgzJqUEYdyuheQ5coo4gy2qGMWpTRFZRRD2Uf6ZT6GKMGY0_Jyc728dYuc606mIonImKxKAMJkaeUoEPBJ2UIrqZWBQQEIg1SGeSy0DAaaVXyQI_FWCqeBioqtErSUsTPyEZVV_oFobHmQR4FMpgEnOcgy8t4zEMehnFeaqGGZNQ92kw5Hntsp3KRYTwLOsnOVIY6yVAnQ_K-l76y_C1r5ChoaZ0IsyKbnQoz92o1WRzaL99pMCRv-9NgovG7m6x03TYZUuQJ8BRDMSTPrer7iTrADAlbwUJmy6AzE8ODQ8nwNjC6MzwQUfRy7ZVekbvLV2yTbMy_t_o1OM7z_I1B8i9wP8Cr |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nonalcoholic+Fatty+Liver+Disease+Is+Associated+With+Coronary+Artery+Calcification+Development%3A+A+Longitudinal+Study&rft.jtitle=The+journal+of+clinical+endocrinology+and+metabolism&rft.au=Park%2C+Hyo+Eun&rft.au=Kwak%2C+Min-Sun&rft.au=Kim%2C+Donghee&rft.au=Kim%2C+Min-Kyung&rft.date=2016-08-01&rft.eissn=1945-7197&rft.volume=101&rft.issue=8&rft.spage=3134&rft_id=info:doi/10.1210%2Fjc.2016-1525&rft_id=info%3Apmid%2F27253666&rft.externalDocID=27253666 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-972X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-972X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-972X&client=summon |